Market News

(Updates with information on Microsoft delivery delays in the headline and the fifth to seventh para

ADMA Biologics reported third quarter 2026 sales of US$141.1 million and net income of US$49.88 million, with basic earnings per share from continuing...

Wall Street's biggest trading desks spent weeks arguing that the stock-market rally would resume once the election was over. On Thursday, that call ba...

Etsy (NYSE: ETSY) announced that Chief Financial Officer Lanny Baker will depart the company, and a transition is already underway. The marketplace op...

Coeur Mining is a Strong Buy, driven by substantial production growth projects and a favorable North American operating landscape. Click for more on C...

Piper Sandler analyst James Fish reiterates Cloudflare (NYSE:NET) with a Overweight and raises the price target from $333 to $337.

Wells Fargo analyst Anthony Trainor maintains Sweetgreen (NYSE:SG) with a Overweight and raises the price target from $11 to $14.

Shell clears a quality dividend screen with a 7/10 dividend rating, a low 25.94% payout ratio, strong cash flow and reasonable valuation.

Wells Fargo analyst Zachary Fadem maintains Best Buy Co (NYSE:BBY) with a Equal-Weight and raises the price target from $85 to $95.

Gold finished October at US$3,913/oz, down 6.3% m/m, with declines across all the major currencies we track.

Align Technology, Inc. ("Align") (NASDAQ:ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® ...

U.S. jobs report beats forecasts as payrolls and wages rise, but labor fragility remains. Click for a look at the report and its implications for mark...

inTest (AMEX:INTT) reported third-quarter financial results on Friday. The transcript from the company’s third-quarter earnings call has been provided...

The 114-key hotel operates via a franchise agreement with ARES İstanbul Turizm.

Wells Fargo analyst Zachary Fadem maintains Texas Roadhouse (NASDAQ:TXRH) with a Overweight and lowers the price target from $230 to $220.

Obsidian Therapeutics, Inc. (NASDAQ:OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop enginee...

The decline in technology stocks doesn't represent a sudden deterioration in the outlook for the sector, UBS said in a note.

Keybanc analyst Jackson Ader maintains Akamai Technologies (NASDAQ:AKAM) with a Overweight and lowers the price target from $195 to $175.

AirSculpt Technologies (NASDAQ:AIRS) reported third-quarter financial results on Friday. The transcript from the company’s third-quarter earnings call...